GCL
SABSW icon

Glazer Capital LLC’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Glazer Capital LLC’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-117,505
Closed -$108K – 853
2021
Q3 		$108K Sell
117,505
-152,834
-57% -$109K ﹤0.01% 749
2021
Q2 		$249K Buy
+270,339
New +$196K ﹤0.01% 715

Other funds holding SABSW

SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Glazer Capital LLC's SABSW Position: Q4 2021 in Review

Glazer Capital LLC sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2021, closing a stake of 117,505 shares — an estimated $108K sold.

Glazer Capital LLC first reported a position in SABSW in Q2 2021 and held it in 2 quarters. The position peaked at $249K in Q2 2021. 21 funds tracked by Wall St. Rank hold SABSW as of Q4 2021.

  • Glazer Capital LLC reported no remaining SAB Biotherapeutics Warrant position as of Q4 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 117,505 SAB Biotherapeutics Warrant shares in Q4 2021, an estimated $108K.
  • Glazer Capital LLC first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 2 quarters.
  • Glazer Capital LLC's SAB Biotherapeutics Warrant position peaked at $249K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.